155 related articles for article (PubMed ID: 37773000)
1. Nintedanib Therapy Alone and Combined with Mycophenolate in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: Systematic Reviews and Meta-analysis.
Herman D; Ghazipura M; Barnes H; Macrea M; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
Ann Am Thorac Soc; 2024 Mar; 21(3):474-485. PubMed ID: 37773000
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
[TBL] [Abstract][Full Text] [Related]
3. Cyclophosphamide in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
Barnes H; Ghazipura M; Herman D; Macrea M; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
Ann Am Thorac Soc; 2024 Jan; 21(1):122-135. PubMed ID: 37772975
[No Abstract] [Full Text] [Related]
4. Tocilizumab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
Ghazipura M; Macrea M; Herman D; Barnes H; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
Ann Am Thorac Soc; 2024 Feb; 21(2):328-337. PubMed ID: 37773003
[No Abstract] [Full Text] [Related]
5. Mycophenolate in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
Herman D; Ghazipura M; Barnes H; Macrea M; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
Ann Am Thorac Soc; 2024 Jan; 21(1):136-150. PubMed ID: 37027538
[No Abstract] [Full Text] [Related]
6. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
Macrea M; Ghazipura M; Herman D; Barnes H; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
Ann Am Thorac Soc; 2024 Feb; 21(2):317-327. PubMed ID: 37772987
[No Abstract] [Full Text] [Related]
8. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Distler O; Highland KB; Gahlemann M; Azuma A; Fischer A; Mayes MD; Raghu G; Sauter W; Girard M; Alves M; Clerisme-Beaty E; Stowasser S; Tetzlaff K; Kuwana M; Maher TM;
N Engl J Med; 2019 Jun; 380(26):2518-2528. PubMed ID: 31112379
[TBL] [Abstract][Full Text] [Related]
9. Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score.
Kuwana M; Allanore Y; Denton CP; Distler JHW; Steen V; Khanna D; Matucci-Cerinic M; Mayes MD; Volkmann ER; Miede C; Gahlemann M; Quaresma M; Alves M; Distler O
Arthritis Rheumatol; 2022 Mar; 74(3):518-526. PubMed ID: 34514739
[TBL] [Abstract][Full Text] [Related]
10. Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
Ghazipura M; Mammen MJ; Herman DD; Hon SM; Bissell BD; Macrea M; Kheir F; Khor YH; Knight SL; Raghu G; Wilson KC; Hossain T
Ann Am Thorac Soc; 2022 Jun; 19(6):1040-1049. PubMed ID: 35499854
[No Abstract] [Full Text] [Related]
11. Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial.
Maher TM; Mayes MD; Kreuter M; Volkmann ER; Aringer M; Castellvi I; Cutolo M; Stock C; Schoof N; Alves M; Raghu G;
Arthritis Rheumatol; 2021 Apr; 73(4):671-676. PubMed ID: 33142016
[TBL] [Abstract][Full Text] [Related]
12. Comparison of nintedanib-induced gastrointestinal adverse events between patients with systemic sclerosis-associated interstitial lung disease and idiopathic interstitial pneumonias.
Imai M; Okabayashi H; Akaike K; Hamada S; Masunaga A; Ichiyasu H; Sakagami T
Respir Investig; 2024 May; 62(3):317-321. PubMed ID: 38395006
[TBL] [Abstract][Full Text] [Related]
13. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™).
Distler O; Brown KK; Distler JHW; Assassi S; Maher TM; Cottin V; Varga J; Coeck C; Gahlemann M; Sauter W; Schmidt H; Highland KB;
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):75-81. PubMed ID: 28664834
[TBL] [Abstract][Full Text] [Related]
14. Interstitial lung disease in patients with systemic sclerosis: what can we learn from the SENSCIS trial?
Assassi S; Tumuluri S; Levin RW
Clin Exp Rheumatol; 2023 Aug; 41(8):1713-1719. PubMed ID: 37534955
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline.
Raghu G; Montesi SB; Silver RM; Hossain T; Macrea M; Herman D; Barnes H; Adegunsoye A; Azuma A; Chung L; Gardner GC; Highland KB; Hudson M; Kaner RJ; Kolb M; Scholand MB; Steen V; Thomson CC; Volkmann ER; Wigley FM; Burlile D; Kemper KA; Knight SL; Ghazipura M
Am J Respir Crit Care Med; 2024 Jan; 209(2):137-152. PubMed ID: 37772985
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCIS trial.
Azuma A; Chung L; Behera D; Chung M; Kondoh Y; Ogura T; Okamoto M; Swarnakar R; Zeng X; Zou H; Meng X; Gahlemann M; Alves M; Kuwana M;
Respir Investig; 2021 Mar; 59(2):252-259. PubMed ID: 33223487
[TBL] [Abstract][Full Text] [Related]
17. Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease.
Kuwana M; Azuma A
Mod Rheumatol; 2020 Mar; 30(2):225-231. PubMed ID: 31747840
[TBL] [Abstract][Full Text] [Related]
18. The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease.
Wollin L; Trinh-Minh T; Zhang Y; Distler JHW
Clin Exp Rheumatol; 2021; 39 Suppl 131(4):134-141. PubMed ID: 33886452
[TBL] [Abstract][Full Text] [Related]
19. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease.
Volkmann ER; Tashkin DP; Roth MD; Clements PJ; Khanna D; Furst DE; Mayes M; Charles J; Tseng CH; Elashoff RM; Assassi S
Arthritis Res Ther; 2016 Dec; 18(1):305. PubMed ID: 28038680
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial.
Seibold JR; Maher TM; Highland KB; Assassi S; Azuma A; Hummers LK; Costabel U; von Wangenheim U; Kohlbrenner V; Gahlemann M; Alves M; Distler O;
Ann Rheum Dis; 2020 Nov; 79(11):1478-1484. PubMed ID: 32759258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
